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Summary
The WA cross-idiotype (XId) is the major XId among human monoclonal rheumatoid factors
(mRF) and is almost always associated with the light (L) chain XId, 17.109, and the heavy (H)
chain XId, G6. A cell line, 35G6, was cloned that bears the WA XId, but shows no reactivity
with immunoglobulin G (IgG) and is negative for the 17.109 and G6 XIds. The 35G6 L chain
appears to be derived from the same V,,IIIJKI genes as most WA mRFs L chains. In contrast
to the WA mRFs H chains in which V1 genes are used, the 35G6 IgM expresses a V.3 gene.
Sequence comparisons with other WA XId-positive mRF suggested several common structural
features that may be related to the WA XId and differences that may relate to lack ofIgG reactivity.
Cells similar to 35G6 have previously been described in pokeweed mitogen-stimulated cell lines
ofperipheral blood lymphocytes from normal individuals and patients with rheumatoid arthritis
and type II mixed cryoglobulinemia. These observations were confirmed, and in addition, it
was shown that the majority of WA XId-positive cells in these cultures were negative for the
17.109 and G6 XIds. The presence of the WA XId in the absence of IgG reactivity suggests
that the WA XId is more directly associated with an antigen specificity other than IgG, and
its association with RF activity may be incidental. It is postulated that these WA XId-positive
RF-negative antibodies may serve a physiologic role as natural antibodies to a pervasive pathogen,
and that IgG reactivity is a consequence of somatic diversification accompanying proliferation
of the WA XId-positive RF-negative cell.
T
he WA cross-idiotype (XId)', the major cross-idiotype
among human monoclonal rheumatoid factors (mRF),
is a conformational antigenic determinant involving both H
and L chains and appears to be located in the antigen binding
site (1, 2). The L chain-associated XId identifiedby the mAb
17.109 and the H chain-associated XId detected by the G6
mAb have been reported to occur in almost all WA XId-
positive mRFs (3) and has led to the notion that there is re-
stricted expression of these germline genes with little or no
1 Abbreviations used in this paper: mRF, monoclonal RF; XId, WA cross-
idiotype.
The sequences reported in this paper havebeen deposited in the GenBank
data base under accession numbers M97268 and M87269.
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somatic mutation in the WA mUs. Earlier, it had been postu-
lated that the VKIIIb L chain detected by 17.109 mAb and
encoded by the Humkv325 gene was the structural basis for
the mRF WA XId and was unique to IgM with RF activity
(4); however, this hypothesis was disproved (2), and it has
been shown that the 17.109 and G6 XIds occur separately
(5) and together (6) in IgM without RF activity.
Although the WA XId occurs in high frequency among
mRF in serum cryoglobulins from patients with type II
cryoglobulinemia, it appears to occur in only small amounts
among polyclonal RFs in patients with rheumatoid arthritis
(7, 8). Although the WA XId has not been reported among
monoclonal IgM immunoglobulins without RF activity,
among polyclonal RFs, WA XId-positive RF-negative Igs
have been reported. WA XId-positive RF-negative plasma
cells were detected in PWM-stimulated PBL cultures from
normal individuals and patients with rheumatoid arthritis
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Volume 178 December 1993 1903-1911(9) andwere also found in synovia of patients with rheuma-
toid arthritis (10). Moreover, a high incidence of WA XId
antigen has been found in RF-negative sera of patients with
juvenile rheumatoid arthritis (11).
In the process of cloning RF-producing cell lines from
normal PBL, we cloned ahybridoma cell that produces a WA
XId-positive IgM that does not exhibit RF activity and is
negative for the 17.109 and G6 XIds. The cell line, 35G6,
and its secreted IgMare characterized in this study. To deter-
mine if the WA XId-positive RF-negative cells previously
observed in normal individuals and patients with rheuma-
toid arthritiswere similar to the35G6 cells, theoriginal PWM-
PBL cultures (9) were reexamined.
Materials and Methods
Cloning of35G6 Rybridoma, IgMIsolation, and Amino Acid Se-
quencing of 35G6 IgM. An enriched B cell population obtained
from a RF-negative normal donor was transformed with EBV by
routine methods. Thebulk culture continuously produced a WA
XId-positive RF-negative IgM from day7to day55 andwas fused
with the F3B6 cell line (American Type Culture Collection, Rock-
ville, MD)on day55. Thefusion productwassubdoned three times
by limiting dilution. Thefinal cell line obtained was monoclonal
by gene arrangement and DNAindenting analyses. The 35G6 IgM
was isolated from thecell culture supernatant by euglobulin precipi-
tation followed by column chromatography on Superose 6 (Phar-
macia, Piscataway, NJ). NH2-terminal amino acid sequence anal-
ysis of 35G6 H and L chains was performed by the Department
of Physiology, TuftsUniversity Analytical Core Protein Sequencing
Facility (Boston, MA).
Antisera.
￿
Goat anti-McD, one of the original antisera to the
WA XId, was raised, absorbed, and characterized (2) in the same
way as therabbit anti-McD (1) (originally anti-Ma) . In addition,
the F(aV)2 preparation from theisolated IgG was affinity purified
on aWA mRF Sepharosecolumn and further absorbed with solid
phase BLA mRF. The final absorbed antisera showed no reaction
with non-RF IgM or PO or BLAmRFs by ELISA assay. Thean-
tisera has the same specificity as the original rabbit anti-McD and
hasbeen the standard polyclonal anti WA XId typing reagent for
the past 15 yr. Themonoclonal antisera Glo 108.12 and Glo 86.3
were kindly provided by Dr. D. Posnett (Cornell University Med-
ical School, NewYork), G6 and G8 that detect VHI-associated XId
(12, 13) and B6 and D12 that detect V3-associated XId (14) were
kindly provided by Dr. R.Jefferis (University of Birmingham Med-
ical School, Birmingham, UK), and 17.109 was kindly provided
by Dr. WKoopman (University of Alabama, Birmingham, AL).
RF-TSI was kindly provided by Drs. I. Randen, K. Thompson,
andJ.Natvig (Institute of Immunology andRheumatology, Oslo,
Norway.
Assays.
￿
WA cross-idiotyping, IgG binding, and immunodot
assays were performed as described (2). The Wa and 35G6 IgM
bindinginhibition ELISA assays were performedin aroutine manner
using F(ab')2 goat anti-McD as the ligand. Biotin-labeled Wa
mRF and 35G6 were prepared by standard methodologies. The
respective biotin preparations that produced a binding of 1 OD
were used forinhibition. Either 25 pl ofWa-biotinor 35G6-biotin
at 2 Wg/ml was incubated with 25 pl of varying concentrations
of inhibitor at room temperature in the coated plate for 2 h. The
plates were then processed in routine manner. Percent inhibition
was determined as follows: 100/OD x (no inhibitor) [OD (no
inhibitor) - OD (inhibitor)].Theamount of inhibition that yields
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Figure 1.
￿
Comparison of35G6 L (A) and H(B) chaincDNA sequences
with theirgermline counterparts. Both strands of thecDNA were sequenced
multiple times. The sequence of the 35G6 cDNA is given. The deduced
single letter aminoacid sequence is givenandnumbered accordingto Kabat
et al. (25) above the nucleotide sequence. The sequence of thegermline
genesis indicated only when amismatch occurs;homologous regions are
indicated by dots. Thenumbering begins at theinitialnucleotide coding
for the first amino acid in the mature protein (asterisk every 10 nucleo-
tides) . The CDR regions are indicated.
50% inhibition is the 150. Comparison of relative I5o is made by
setting the 150 of WA mRF at 1.0.
The competitive inhibition assay for VIIIb was performed as
previously described (15). The assays for the 17.109 XId, V1-
associated XIds using the G6 or GS mAbs, and the V.3-associated
XIds usingtheB6 or D12 mAbs andGlo antigens using Glo 86.3
mAb were performedin the same way. In addition, Glo 86.3 was
tested directly for reactivity with 35G6. The Wa mRF was used
as the ligand for the V.1-XId assay; the Glo protein was used as
the ligand for the 17.109 XId, V.3-XId, and Glo assays. Assays
forviralAb activities (cytomegalic, hepatitis A, B, andC, andHIV1)" Subgroup class.
t Number of amino acids.
andvarious autoantibodies (antinuclear, thyroglobulin, microsomal,
cyoplasm, DNA, DNA histones, and BSA Abs) were performed
by routine methods.
PWM-inducedplasma cellsandstaining ofplasma cellsfor IgG,
WA XId, and aggregate IgGbindinghasbeen previously described
in detail (9). Staining with mAbs 17.109 or G6 were done in the
same way except that a fluorescein-labeled F(ab')2 anti-mouse was
used as a second Ab. Slides of cell samples from the original cul-
tures and additional cultures prepared in the same laboratory at
about the same time as the originals were stored at -70°C until
used in this study.
Oligonucleotides.
￿
The following oligonucleotide primers were
used: V.3 FRl, TCCCTGAGACTCTCCTGTGC; VH3 Leader,
GCTGGCTTTTTCTTGTGGCT it constant (CM-31), GGA-
ATTCTCACAGGAGACGA; P, constant (CHl-24), TCACAG-
GAGACGAGGGGGAA; VK3 FR1, GGCACCCTGTCTTTG-
TCTCCA; VXIII Leader, TCCTCCTGCTACTCTGGCTCC; K
constant, CTCATCAGATGGCGGGAAGAT, and V-D junction,
TCTATTACTGTGCGGCCGCC.
RNA-PCRandDNASequencing.
￿
Total RNAwasprepared by
standard methods. Reversetranscription, using 20 pmol u- or P,-C
region primer or 100 pmol random hexamer primer, and 200 U
MoMuLV reverse transcriptase (Superscript RNase H-; Bethesda
Research Laboratories, Gaithersburg, MD), andPCRamplification
for 30 cycles with a thermal profile of 1 min at 94°C, 1 min at
51°C for H chain primers or 1 min at 55°C for L chain primers,
and the V-D junction/IA constant (CHl-24) primer pair, and 1
min at 72°C, was performed (16). Asymmetric PCR (17, 18)was
performed similarly except that a 1:20 ratio of primers was used
for 40 cycles. Both strands of each cDNA were sequenced with
Sequenase(US. Biochemical, Cleveland, OH)in replicate with each
primer. Direct sequencing was employed rather than sequencing
cloned PCR products to minimize potential PCR artifacts (18).
35G6 DNAsequenceswere compared with sequencesfoundin Gen-
Bank (release 69).
Results
Characterization of the 35G6 Cell Line and IgM
Protein Analysis.
￿
The 35G6 clone produced only IgM,,
immunoglobulin. By NH2-terminal amino acid analysis, the
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first 21 amino acidsoftheLchainwere identicalto theproduct
of the VJII gene Humkv325 (19), and the first 19 amino
acids of the H chain were identicalto theproduct of theVH3
gene, VH26 (20) .
Sequence of the L Chain.
￿
The sequence for the L chain
mRNA/cDNA (Fig. 1 A) revealed a close homology with
the VKIIlb germline L chain gene Humkv325 (19) (97.9%
homology). The six point mutations in the coding region
resulted in four changes in the amino acid sequence; each
of the CDR has a change in amino acid, as does FR2. No
mutations were found in the JK1 gene. Compared with
Humkv325, an additional codonwas foundat theVJjunction.
Sequence ofthe H Chain.
￿
The sequence for the H chain
mRNA/cDNA (Fig. 1 B) revealed a close homology with
the VH3 germline gene VH26 (96.6% homology) (20). Ten
base changeswere observed and three3' terminal nucleotides
oftheV gene appear to have been deleted. Four of thechanges
coded for amino acid changes: one in FR1, two in CDR1,
and one in CDR2. The D region could not be assigned to
a specific D gene and a JH4 gene was utilized, which con-
tained two point mutations.
Further confirmation of the sequence for the V-D junc-
tion of 35G6 H chain mRNA was obtained by performing
an RNA-PCR with an oligonucleotide spanning the V-D
junction and the p, constant primer (CH1-24) at stringent
annealingconditions whichwouldpermit amplification only
if the V-D junction primer annealed along its full length
without interruption or mismatch. The anticipated 130-bp
product (data not shown) was obtained.
Comparison of 35G6 and WA mRFs V Genes.
￿
Previous
studies (21-23) of genes associated with the WA XId have
noted the essential role of VJIIb genes, the preferential use
ofJKI, V1, andJH4 genes, and a 9-10 amino acid beginning
with glutamic acid andending with proline. 35G6 similarly
utilizes VIIlbJKI genes and a nine-amino acid D ending
in proline linked to JH4 but lacks the initial glutamic acid
in D and uses a VH3 instead of a VH1 gene (Table 1).
The NH2-terminal JH4 residue of 35G6 (amino acid 100)
Table 1.
mRF
Comparison of 35G6 to
V
WA and Vx3 mRFs
D JH VK JK WA XId
35G6 3" 9t 4" 3b 1 +
Bor 1 9 4 3b 1 +
Kas 1 9 4 3b 1 +
Sie 1 10 4 3b 1 +
Wol 1 9 4 3b 1 +
RF-TS1 1 11 3 3b 1 +
Lay 3 10 1 1 -
Pom 3 10 1 3a -
Riv 3 12 6 3a -Figure 2 .
￿
WA cross-idiotype (XId) inhibition assays. Inhibition ofpoly-
clonalWA XId reagent, goat anti-McD by varying concentrations ofWA
mRF (A), 35G6 IgM (*), and Bla mRF (" ) are plotted.
is tyrosine rather than phenylalanine, but Wol, a WA mRF,
also has a tyrosine at this position . The only WA mRF
reported to use a JH gene other than JH4 is RF-TS1, which
uses a J3 gene. J.3 is the same length as JH4 and bears the
closest homology toJA of the J genes . The presence ofJ3
does not affect the reactivity ofRF-TS1 withG6 or G8 (24)
or with the WA XId reagent in this study.
Another difference between 35G6 IgM and otherWA pro-
teins is that the arginine (position 94) at the V-D junction
Figure 3 . WA cross-idiotype (XId) immunoblot assay. Duplicate
nitrocellulose strips were dotted with WA mRF, WA mRF heated (A),
35G6, 35G6 heated (A), Bla mRF, and Bla mRF heated (A) . Top strip
was stained for protein with Coomassie blue . Bottom strip was probed
with goat anti-McD.
has been deleted (Fig. 1 B ; GenBank, release 69) . The argi-
nine at 94 is also common in PO mRFs (25) .
Serologic studies of the 35G6 IgM
￿
The 35G6 IgM was
shown to have the WA XId antigen by both ELISA (Fig .
2) and immunoblot analysis (Fig . 3) . Quantitative WA XId
analysis showed 1 Ftg/ml of35G6 IgM to give the same inhi-
bition as 0.85 Fig/ml of WA mRF (Table 2) . Considering
the 10% variation of the assay, essentially all of the 35G6
IgM bears theWA XId . Direct comparison of the presence
of WA XId antigen using either Wa mRF or 35G6 IgM
binding to the same anti-WA XId reagent (goat anti-McD)
showed essentially the same relative 150 (Table 2) .
35G6IgM showed noRF activity in concentrations < 100
fr.g/ml in an IgG binding assay that could detect as little as
0.01 Ag/ml ofmRF and also lacked the L and H chain XId
associated withWA mRFs . The 35G6 IgM had -10% of
the reactivity ofWA mRFs with the 17.109mAb by inhibi-
tion assay. The weak reactivity of 17.109 with 35G6 IgM
was confirmed by the failure to demonstrate reactivity by di-
Table 2 .
￿
Comparison of Inhibition of WA mRF, 35G6 IgMBinding to Anti-WA XId (F[ab']Z goat anti-McD), Monoclonal 17.109 to
Glo mRF, and Monoclonal G6 Binding to WA mRF by Various Monoclonal RFs
150, WA mRF = 1.0 .
tWA mRF .
S BLA mRF .
II Non-RF mIgM .
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mRF
Inhibitor WA mRF
Relative inhibition
35G6 IgM 17.109 G6
35G6 1 .2' 0.8 9.2 >200
Wat 1 .0 1 .0 1 .0 1.0
Glot 0.5 0.5 0.4 >200
Gol 0.6 ND 4.6 135
McDf 0.6 0.6 2.5 4.6
Bias >10.0 >10.0 >16 >200
PUP >10.0 >10.0 >16 >200
Shall >10.0 >10.0 >16 >200rect binding ELISA or immunoblot assays. Glo, Gol, and35G6
L chain sequences differ from that of Sie (the immunogen
for 17.109) by 4, 8, and 11 residues (GenBank, release 69),
respectively. Comparison of reactivities of these proteins with
17.109 and anti-WA XId (Table 2) indicates that a few amino
acid changes in the VKIII L chain can greatly reduce reac-
tivity with 17.109, although they do not affect reactivity with
the anti-WAXId . For example, Glo and Gol had almost iden-
tical reactivities with anti-WA XId, but Gol had <10% of
the reactivity with 17.109 shown by Glo . As expected, both
35G6 IgM and Glo mRF did not inhibit G6 binding because
both possess V3H chains, but it is notable that, of fiveWA
mRFs, only two were G6 positive, and one of these (McD)
was only weakly positive (Table 2) . The 35G6 IgM did not
inhibit the B6 and D12 V.3-associated XId assays and did
not react with mAb Glo 86.3, which has been shown to have
reactivity with theWA mRFs and Po mRF, a V3 protein
(26) (data not shown) . No viral or autoantigen reactivity was
found with 35G6 IgM . The 35G6 IgM did react with
staphylococcal protein A, as do most IgM with V3 H
chains (27) .
Immunofluorescence Studies ofPWM-stimulated PBLs from
Normal Individuals and Patients with RA . WA XId-positive
RF-negative plasma cell cultures from PWM-stimulated PBL
from normal individuals and patients with RA (four HL,
Table 3 .
￿
Cytoplasmic Igs and WA XId Detected in RA and Control Cells after 6-d Culture ofPBL with PWM
Percent
￿
Percent WA XId
plasma cells
￿
positive cells of
RF Patient
￿
of total cells
￿
total plasma cells
BB, NA, and BB from the original study [9] and seven addi-
tional cultures) were reexamined for WA, 17.109, and G6
XId antigens, and aggregated IgG binding (Table 3) . The
previous findings thatWA XId-positive cells were negative
for aggregated binding were confirmed . In the entire study,
only a rareWA XId-positive cell was found with aggregated
IgG binding . The percentage of cells that were positive for
17.109 andG6 was similar but substantially less than the ob-
served percentage ofWA XId-positive cells . Cells from pa-
tient DE were also tested with anti-McD and mAb 17.109
absorbed in the same manner and with the same normal human
serum (NHS) used in the original study, i.e., 12% NHS was
added to each antiserum (9) .WA XId-positive cells decreased
from 24 to 18% . There was no change in4% positive 17.109
cells . The relatively small drop in the percentage ofWA XId-
positive cells in this study (6%) compared with the sample
in the original study(45%) is most likely attributable to the
more complete absorption of the antisera in this study,
resulting from the more sensitive assays used for the detec-
tion of contaminating Abs, i .e ., ELISA versus hemagglutinin .
By double-staining analysis, the majority of WA XId-
positive cells were negative for both 17.109 and G6 ; all cells
positive for 17.109 or G6 were also positive forWA XId (data
not shown) . The percentages of cells reactive withWA XId
and either 17.109 or G6 were not altered by the order of
Percent 17.109
positive cells of
all plasma cells
Percent G6
￿
Percent cells
positive cells
￿
binding aggregated IgG
of all plasma cells
￿
of all plasma cells
' Data indicate the percentage of cells showing cytoplasmic staining with fluorescent anti-human Igs (see Materials and Methods), as counted among
100 total cells identified by phase contrast .
t Data indicate the percentage of cells showing WA XId stained with anti McD and fluorescein-conjugated second Ab (see Materials and Methods),
as counted among 100 Ig-containing cells identified by staining with rhodamine-conjugated antitotal human Ig Abs .
S Data indicate the percentage of cells stained with either mouse monoclonal 17.109 or mouse monoclonal G6 and fluorescein-conjugated second
Ab (see Materials and Methods), as counted among 100 Ig-containing cells identified by staining with rhodamine-conjugated antitotal human Ig Abs .
II Data indicates the percentage of cells binding fluorescein-conjugated IgG, as counted among 100 Ig-containing cells identified by staining with
rhodamine-conjugated antitotal human Ig Abs .
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DU 14.5" 33# 7S 7S 011
HL 12.6 15 6 11 0
BB 10.6 10 4 ND 0
FE 11.2 46 4 8 0
DE 25.0 24 4 1 0
QT 10.0 8 0 3 0
AL 36.0 33 14 13 0
VI 11.8 27 3 10 0
Control
NA 13.3 4 <1 <1 0
BP 15.0 3.3 1 .5 1 .0 0
VB 14.2 3.5 1 .3 0.98 0Figure 4 .
￿
Immunofluorescence of plasma cells from 5 d PWM cultures from PBL from an RA patient . Staining with fluorescein conjugates for
WA XId and rhodamine conjugates for 17.109 . (A) PWM cultures, selective illumination for fluorescein ; several plasma cells show WA Xld . (B) Same
as A : selective illumination for rhodamine ; only one cell shows 17.109 . x500 .
staining with the anti-McD and mAb 17.109 mAb G6 . An
example of the paucity of 17.109-positive cells among WA
XId-positive cells is illustrated in Fig. 4 .
Discussion
These studies indicate that the conformational H-L chain
antigen that constitutes theWA XId is not restricted to RFs
and does not require the presence of the 17.109 or G6 XIds .
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Furthermore, certain VH3 as well as V1 H chains can
generate the WA XId .
The data presented in this study, which demonstrate that
relatively few mutations in theHum6325 gene markedly de-
crease the expression ofthe 17.109 XId without affecting the
WA XId, indicate that previous conclusions regarding the
prevalences ofWAmRFs based on serologic studies withmAb
17.109 are not valid. Also, from dual staining immunofluores-
cent studies with theWA XId reagent and either 17.109 orG6 reagent, neither the 17.109 nor G6 epitopes appear to
be part of the WA XId epitope(s).
Comparison of 35G6 L and H chain structure with those
of WA and other mRFs suggests that the WA XId is deter-
mined by structural motifs contributed by a conserved FR3
present on VH1 and VH3 H chains, a discrete-sized D region,
and use of JH3 or Jy4 in combination with specific VKIIIb L
chains. Of interest regarding the discrete-sized D region re-
quirement is the recent report that 17.109 positive G6 posi-
tive IgM without RF activity produced in transfectomas have
marked variability in the length of the D region (6). Because
all 17.109, G6 mPLFs previously studied have been WA XId-
positive, the requirement of the discrete-sized D region can
be tested by assaying these transfectoma IgMs for WA XId.
From comparative studies of 35G6 with Wa mRF, IgG
reactivity appears to be related to the presence of arginine
at position 94 and glutamine at position 95 in Wa mRF
H chains. The presence of an extra proline at the V,-J,, junc-
tion in 35G6 is against the hypothesis that such an additional
proline is important for RF activity (27). An additional amino
acid at the V.-J,, junction is relatively uncommon, and it has
been proposed that the mechanism for generation of such
additional amino acids may be an abnormal process (28). The
additional amino acid at this position in a human Ab from
normal individuals (29) and in the 35G6 IgM that was gener-
ated from a normal individual indicates that the mechanism
involved is more likely a normal one.
The original explanation (9) for the observation that WA
XId-positive RF-negative cells are present in PWM-stimulated
(PBL) cultures was that pentameric IgM capable of binding
aggregated IgG was not present in these cells. Our finding
that the 35G6 cell line produces a WA XId-positive RF-
negative IgM suggests an alternative explanation that the WA
XId-positive RF-negative cells are progenitors of the cells
that do produce WA XId-positive RF-positive IgM. The high
prevalence of WA XId-positive cells in PWM-PBL cultures
compared with the prevalences of 17.109-positive and G6-posi-
tive cells may be due to somatic mutation of the germline
genes that encode the 17.109 and G6 XIds or may indicate
that other genes encode the WA XId. The data demonstrating
that relatively few mutations in the Humkv325 gene greatly
decrease the expression of 17.109 XId without affecting the
WA XId, and the rarity of expression of genes other than
Humkv325 in Wa mRF, favor the former possibility.
It was initially thought that increased prevalence of WA
XId-positive plasma cells in patients with rheumatoid arthritis
may be related to the disease process, but small amounts of
17.109 XId and G6 XId found in the blood were interpreted
as against this possibility (4). The finding that with somatic
mutation the 17.109 XId is lost and the WA XId retained,
coupled with studies that demonstrated overexpression ofso-
matically mutated Humkv325 genes in synovial tissue (28),
indicate that the absence of 17.109 and G6 XIds does not
exclude Wa mRF.
Pernis et al. (10) have suggested that the WA XId-positive
RF-negative cell represents a regulatory cell type. The pres-
ence of a molecule with the WA XId but without IgG reac-
tivity would permit modulation of anti-WA XId without
the presence of RF in the circulation. The identification of
WA XId-positive RF-negative cells in normal individuals and
in patients with rheumatoid arthritis may be consistent with
the hypothesis that the WA XId-positive RF-negative IgM
cell modulates suppression of RF production. The detection
of WA XId-positive RF-negative IgM cells in patients with
juvenile rheumatoid arthritis may reflect this suppression (11).
However, ifthis hypothesis were correct, the WA XId-positive
RF-negative cell would be absent or reduced in patients with
essential mixed cryoglobulinemia; this is not the case (9).
An alternative hypothesis is that the WA XId-positive RF-
negative cell has a physiologic role, which is the secretion
of natural Ab to a common pathogen, and that RF activity
is a cross-reactivity that develops with somatic mutation ac-
companying proliferation of these cells. Both the serologic
data on Wa mRFs and the immunofluorescent studies on the
PWM-stimulated cells indicate that the WA XIds are preserved
in the presence of mutation of the germline genes that en-
code the 17.109 and G6 XIds. Ifthe main association of cross-
idiotypes is with antigen specificity of the Ab as first described
(30, 31), then conservation of the WA XId suggests an an-
tigen selection process for WA XId-positive cells. The recent
finding of chronic hepatitis C virus (HCV) infection in pa-
tients with mixed cryoglobulinemia (32) suggests that HCV
may be the pathogen that stimulates proliferation of the WA
XId-positive RF-negative cells.
The mRFs encoded by germline genes have been found
to cross-react with non-IgG antigens (15, 33). The finding
that random pairing of 17.109 L chains and G6 H chain did
not produce IgM with RF activity and that certain somatic
mutations ofCDR3 are required for generation of reactivity
with IgG and other self-antigens (6) is consistent with the
possibility that the germline genes that encode the 17.109-
positive G6-positive IgM are preserved by selection for reac-
tivity with antigens other than IgG. Hence, the RF activity
ofWA mRFs may be incidental and unrelated to the physio-
logic role of these Abs but may play a role in disease as a
result of untoward proliferation and involvement in immune
complex-mediated inflammation.
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